- Home
- ARMP vs DMA Comparison
ARMP vs DMA Comparison
Compare ARMP & DMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- DMA
- Stock Information
- Founded
- ARMP N/A
- DMA 2011
- Country
- ARMP United States
- DMA United States
- Employees
- ARMP N/A
- DMA N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- DMA Trusts Except Educational Religious and Charitable
- Sector
- ARMP Health Care
- DMA Finance
- Exchange
- ARMP Nasdaq
- DMA Nasdaq
- Market Cap
- ARMP 92.4M
- DMA 78.0M
- IPO Year
- ARMP N/A
- DMA N/A
- Fundamental
- Price
- ARMP $2.86
- DMA $8.76
- Analyst Decision
- ARMP Strong Buy
- DMA
- Analyst Count
- ARMP 1
- DMA 0
- Target Price
- ARMP $9.00
- DMA N/A
- AVG Volume (30 Days)
- ARMP 12.1K
- DMA 34.6K
- Earning Date
- ARMP 11-12-2025
- DMA 01-01-0001
- Dividend Yield
- ARMP N/A
- DMA 2.04%
- EPS Growth
- ARMP N/A
- DMA N/A
- EPS
- ARMP N/A
- DMA N/A
- Revenue
- ARMP $6,868,000.00
- DMA N/A
- Revenue This Year
- ARMP $8.43
- DMA N/A
- Revenue Next Year
- ARMP N/A
- DMA N/A
- P/E Ratio
- ARMP N/A
- DMA N/A
- Revenue Growth
- ARMP 84.67
- DMA N/A
- 52 Week Low
- ARMP $0.90
- DMA $4.78
- 52 Week High
- ARMP $3.14
- DMA $8.00
- Technical
- Relative Strength Index (RSI)
- ARMP 57.54
- DMA 59.52
- Support Level
- ARMP $2.79
- DMA $8.55
- Resistance Level
- ARMP $3.03
- DMA $8.83
- Average True Range (ATR)
- ARMP 0.16
- DMA 0.07
- MACD
- ARMP 0.01
- DMA 0.01
- Stochastic Oscillator
- ARMP 62.16
- DMA 76.09
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.